The first thing you notice walking into the new wholesale market in Ukiah is that it smells like nothing at all. Air-handlers the size of small trucks pull every molecule of terpene out of the room before it can reach a nostril, a customer, or — most importantly — an inspector. This is the great paradox of legal cannabis in 2026: it has never been more available, and it has never been more contained.

Across town, an unlicensed grower named Buddy is rolling a joint the size of a sharpie on the hood of his Tacoma. He does not know what terpenes are. He does not need to. The flower is from a clone given to him in 1994 by a man named Wookie who is now, depending on who you ask, either dead or in Belize.

“We didn't legalize a plant. We legalized a particular relationship to a plant — and excluded everyone whose relationship was older.”

The federal rescheduling, announced last August and quietly implemented in March, was supposed to fix this. In some ways it did. Hemp-derived novel cannabinoids — the gas-station gray market that ate the industry's lunch from 2020 to 2024 — are now subject to the same testing standards as licensed flower. Banking, finally, is normal. A dispensary in Cleveland can now accept a debit card without routing the transaction through a Polish subsidiary.

But the people we spoke with — sixty-three of them, across nine months — kept coming back to a different question. Not is it legal, but whose? Continued on Page A-14 ➞